Please ensure Javascript is enabled for purposes of website accessibility

Welcome to Regulatory Rapporteur. This site uses cookies. Read our policy.

  • Skip to main content
  • Skip to navigation
Site name
topra-logo

The Organisation for Professionals in Regulatory Affairs
Site name
Mast navigation
  • Become a member
  • Sign in
Search our site
Menu
Close menu
  • Home
  • Medical devices
    • Back to parent navigation item
    • Medical devices
    • Combination products
    • In-vitro diagnostics
    • Software
  • Pharmaceuticals
    • Back to parent navigation item
    • Pharmaceuticals
    • ATMP
    • Chemistry, manufacturing and controls
    • Clinical trials
    • Non-clinical development
    • Product information
    • Regulatory procedures
  • Veterinary
  • CPD supplements
  • Interviews
  • Meeting reports
  • Editorials
  • topra-logo

    The Organisation for Professionals in Regulatory Affairs
  • Home
  • Medical devices
      • Combination products
      • In-vitro diagnostics
      • Software
    • AdobeStock_264649866
      Translating digitalisation trends into tangible solutions
    • AdobeStock_474265160
      What can past decision-making data tell us about how the FDA will make future combination product categorisation decisions?
    • AdobeStock_405906571-min
      Practical insights into the recent EU MDR framework
  • Pharmaceuticals
      • ATMP
      • Chemistry, manufacturing and controls
      • Clinical trials
      • Non-clinical development
      • Product information
      • Regulatory procedures
    • AdobeStock_393791829
      Data governance as a strategic imperative for regulatory compliance
    • AdobeStock_286032180
      Exploring Amgen’s Project Orbis experience with sotorasib (Part 2)
    • AdobeStock_244609855
      A regulatory view on the change management process for medicinal products
  • Veterinary
  • CPD supplements
  • Interviews
  • Meeting reports
  • Editorials
  • More navigation items

Product Information Stories

  • AdobeStock_180072866

    Part 1: EU reclassification (Rx to OTC switch) regulatory framework – what are the key challenges for industry and how might these be overcome?

    2022-06-22T14:53:00+01:00By Sarah Landra (née Laird)

  • AdobeStock_294542021

    Electronic leaflet pilot in Belgium and Luxembourg hospitals

    2022-03-23T11:07:00+00:00By Nathalie Lambot, Marie Vande Ginste

  • Editorial board
  • Future features
  • Glossary
  • Privacy policy
  • Search the archive
  • TOPRA membership
  • What is regulatory affairs?

Regulatory Rapporteur

The peer-reviewed journal, published 11 times per year and available free to TOPRA members.

Follow TOPRA
topra-logo

The Organisation for Professionals in Regulatory Affairs

TOPRA office
TOPRA Publishing, 6th Floor, 3 Harbour Exchange, South Quay, London E14 9GE, UK
Tel: +44 (0) 20 7510 2560
Email: publications@topra.org

TOPRA AISBL
Blvd du Souverain 280, 1160 Brussels, Belgium Tel: +32 (0) 2 808 72 70

  • Issues
  • Contact us
  • Topics A-Z
  • Contributors A-Z
  • © 2022 Regulatory Rapporteur

Site powered by Webvision Cloud